Physician profile
Steven D Leon
NPI 1184712697
$1,730.46
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $283 · 2022: $603 · 2023: $616 · 2024: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $697 · Education: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $696.54 |
| Education | $147.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $526.76 | 2021-2024 | Winlevi, Ilumya |
| Mayne Pharma Commercial LLC | $216.00 | 2021-2024 | |
| Lilly USA, LLC | $144.64 | 2021-2023 | Olumiant, Taltz |
| Regeneron Healthcare Solutions, INC. | $113.70 | 2023 | Dupixent |
| Almirall LLC | $111.30 | 2022 | |
| Genzyme Corporation | $96.68 | 2022-2023 | |
| Amgen INC. | $93.17 | 2021-2023 | Otezla |
| Revance Therapeutics, INC. | $75.99 | 2024 | Daxxify |
| Incyte Corporation | $54.55 | 2022-2023 | Opzelura |
| Novartis Pharmaceuticals Corporation | $52.57 | 2021-2022 | |
| Abbvie INC. | $51.79 | 2023-2024 | |
| Pfizer INC. | $50.13 | 2021-2023 | |
| Janssen Biotech, INC. | $49.64 | 2021-2024 | Tremfya |
| Epi Health, LLC | $33.58 | 2022 | |
| Dermavant Sciences, INC. | $25.52 | 2023 | Vtama |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $21.21 | 2021 | |
| Jazz Pharmaceuticals INC. | $13.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Leon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.